DE69334294D1 - Antikörper für die Behandlung von einer Immunerkrankung - Google Patents

Antikörper für die Behandlung von einer Immunerkrankung

Info

Publication number
DE69334294D1
DE69334294D1 DE69334294T DE69334294T DE69334294D1 DE 69334294 D1 DE69334294 D1 DE 69334294D1 DE 69334294 T DE69334294 T DE 69334294T DE 69334294 T DE69334294 T DE 69334294T DE 69334294 D1 DE69334294 D1 DE 69334294D1
Authority
DE
Germany
Prior art keywords
ablation
antibodies
treatment
bone marrow
immune disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69334294T
Other languages
English (en)
Inventor
Milton David Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25348415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69334294(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of DE69334294D1 publication Critical patent/DE69334294D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1036—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1039—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
DE69334294T 1992-04-07 1993-04-02 Antikörper für die Behandlung von einer Immunerkrankung Expired - Lifetime DE69334294D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/866,789 US5776093A (en) 1985-07-05 1992-04-07 Method for imaging and treating organs and tissues

Publications (1)

Publication Number Publication Date
DE69334294D1 true DE69334294D1 (de) 2009-10-15

Family

ID=25348415

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69334293T Expired - Lifetime DE69334293D1 (de) 1992-04-07 1993-04-02 Verfahren und Kit zur Bilderzeugung von Organen und Geweben, worin markierte Antikörper verwendet werden
DE69334294T Expired - Lifetime DE69334294D1 (de) 1992-04-07 1993-04-02 Antikörper für die Behandlung von einer Immunerkrankung
DE69333658T Expired - Lifetime DE69333658T2 (de) 1992-04-07 1993-04-02 Verfahren zur behandlung von organen und gewebe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69334293T Expired - Lifetime DE69334293D1 (de) 1992-04-07 1993-04-02 Verfahren und Kit zur Bilderzeugung von Organen und Geweben, worin markierte Antikörper verwendet werden

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69333658T Expired - Lifetime DE69333658T2 (de) 1992-04-07 1993-04-02 Verfahren zur behandlung von organen und gewebe

Country Status (13)

Country Link
US (8) US5776093A (de)
EP (4) EP1375519A3 (de)
JP (4) JPH07508974A (de)
AT (3) ATE441667T1 (de)
AU (3) AU674846B2 (de)
CA (1) CA2133833C (de)
DE (3) DE69334293D1 (de)
DK (2) DK0637933T3 (de)
ES (1) ES2229207T3 (de)
HK (1) HK1062647A1 (de)
IL (5) IL105302A (de)
PT (1) PT637933E (de)
WO (1) WO1993019668A1 (de)

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
EP1304085A3 (de) * 1994-09-16 2004-01-21 Ethicon Endo-Surgery, Inc. Aus biologisch abbaubarem Material hergestellte Gewebemarkierungsvorrichtung
US6102904A (en) * 1995-07-10 2000-08-15 Interventional Technologies, Inc. Device for injecting fluid into a wall of a blood vessel
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US20040005645A1 (en) * 1996-05-30 2004-01-08 The Regents Of The University Of Michigan Protein markers for esophageal cancer
US6986942B1 (en) 1996-11-16 2006-01-17 Nanomagnetics Limited Microwave absorbing structure
US6815063B1 (en) 1996-11-16 2004-11-09 Nanomagnetics, Ltd. Magnetic fluid
US6713173B2 (en) 1996-11-16 2004-03-30 Nanomagnetics Limited Magnetizable device
GB2319253A (en) 1996-11-16 1998-05-20 Eric Leigh Mayes Composition, for use in a device, comprising a magnetic layer of domain-separated magnetic particles
US20060003163A1 (en) * 1996-11-16 2006-01-05 Nanomagnetics Limited Magnetic fluid
US6821516B1 (en) * 1997-07-18 2004-11-23 I.D.M. Immuno-Designed Molecules Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
US6171856B1 (en) * 1997-07-30 2001-01-09 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
US6205352B1 (en) 1997-11-19 2001-03-20 Oncology Innovations, Inc. Sentinel node identification using non-isotope means
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
OA11917A (en) 1998-12-23 2006-04-13 Abgenix Inc Human monoclonal antibodies to ctla-4.
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US9669113B1 (en) 1998-12-24 2017-06-06 Devicor Medical Products, Inc. Device and method for safe location and marking of a biopsy cavity
US6371904B1 (en) 1998-12-24 2002-04-16 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US6356782B1 (en) 1998-12-24 2002-03-12 Vivant Medical, Inc. Subcutaneous cavity marking device and method
IL146005A0 (en) 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7074403B1 (en) * 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
IL146801A0 (en) * 1999-06-11 2002-07-25 Pro Duct Health Inc Gel composition for filling a breast milk duct prior to surgical excision of the duct or other breast tissue
US6489312B1 (en) * 1999-06-15 2002-12-03 Medimmune Oncology, Inc. Pharmaceutical formulations comprising aminoalkyl phosphorothioates
AU5905400A (en) 1999-07-14 2001-02-05 Board Of Regents, The University Of Texas System Methods and compositions for delivery and retention of active agents to lymph nodes
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2589418A1 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
HRP990264A2 (en) 1999-11-02 2001-06-30 Josip Paladino Neurosurgical endoscopic ultrasonic contact probe
US6835370B2 (en) * 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20050123545A1 (en) * 1999-11-08 2005-06-09 Wands Jack R. Diagnosis and treatment of malignant neoplasms
US20030031670A1 (en) * 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US7097826B2 (en) * 1999-12-23 2006-08-29 Health Research, Inc. Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US7897140B2 (en) * 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US6445945B1 (en) 2000-06-26 2002-09-03 André Arsenault Non-invasive detection of endothelial dysfunction by blood flow measurement in opposed limbs using tracer injection
AU2002225959A1 (en) * 2000-11-09 2002-05-21 Mayo Foundation For Medical Education And Research Absolute lymphocyte recovery and cancer survival
CA2429781C (en) * 2000-11-29 2011-01-11 Bracco International B.V. Linkable sialyl lewis x analogs
EP1372741B1 (de) * 2001-03-30 2006-08-09 University of Massachusetts Morpholinobildgebung und therapie
EP2335728A1 (de) * 2001-05-11 2011-06-22 Ludwig Institute for Cancer Research Ltd. Spezifische Bindeproteine und deren Verwendungen
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
WO2002096460A1 (en) * 2001-05-30 2002-12-05 Cornell Research Foundation, Inc. Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP4619651B2 (ja) 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
JP2004538269A (ja) * 2001-06-11 2004-12-24 ユニバーシティー オブ マイアミ 移植寛容を達成することにおける放射性医薬品複合体の使用
US7951061B2 (en) * 2001-07-25 2011-05-31 Allan Foreman Devices for targeted delivery of thermotherapy, and methods related thereto
US6997863B2 (en) * 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7731648B2 (en) * 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
JP2005527474A (ja) 2001-09-20 2005-09-15 コーネル リサーチ ファンデーション インコーポレーテッド 前立腺特異的膜抗原に特異的な結合剤を用いて、皮膚障害を治療するかまたは防止するための方法および組成物
US7769432B2 (en) * 2001-12-10 2010-08-03 Board Of Trustees Of The University Of Arkansas Minimally invasive diagnosis and treatment for breast cancer
US6578724B1 (en) * 2001-12-29 2003-06-17 United States Can Company Connector for use in packaging aerosol containers
EP2067472A1 (de) * 2002-01-02 2009-06-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
AU2003208415B2 (en) 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
DK1483294T3 (da) 2002-03-01 2010-11-08 Immunomedics Inc Internaliserende anti-CD74-antistoffer og fremgangsmåder til deres anvendelse
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
WO2003077865A2 (en) * 2002-03-15 2003-09-25 Baxter International Inc. Methods and compositions for directing cells to target organs
SI1503794T1 (sl) * 2002-04-12 2012-09-28 Medarex Inc Postopek zdravljenja z uporabo ctla-4 antiteles
CA2488753A1 (en) * 2002-06-07 2003-12-18 Immunomedics, Inc. Neutrophil imaging methods in cyctic fibrosis
US20030228256A1 (en) * 2002-06-11 2003-12-11 Inverardi Luca A. Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations
EP2301968A3 (de) 2002-06-14 2011-06-29 Immunomedics, Inc. Humanisierter monoklonaler Antikörper HPAM4
CA2490692A1 (en) 2002-06-27 2004-01-08 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
AU2003249742A1 (en) * 2002-07-02 2004-01-23 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
EA008683B1 (ru) 2002-07-23 2007-06-29 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
KR101115797B1 (ko) * 2002-08-01 2012-07-27 이뮤노메딕스, 인코오포레이티드 알파 태아 단백질 Ｉｍｍｕ31 항체 및 융합단백질, 및이들의 이용 방법
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
MXPA05003843A (es) * 2002-10-10 2006-02-17 Us Dept Veterans Affairs Deteccion, localizacion y determicnacion de fases de tumores usando linfocitos activados rotulados dirigidos a un epitope especifico.
DE60336406D1 (de) 2002-10-16 2011-04-28 Purdue Pharma Lp Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
US20040138428A1 (en) * 2002-10-18 2004-07-15 Gerardo Zapata System and method for cleaving antibodies
US20040136998A1 (en) * 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
US20060173283A1 (en) * 2002-11-27 2006-08-03 Oskar Axelsson Method of magnetic resonance imaging
EP1578799B8 (de) 2002-12-02 2011-03-23 Amgen Fremont Inc. Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
ES2314272T3 (es) 2003-01-10 2009-03-16 Millennium Pharmaceuticals, Inc. Metodos para el diagnostico y el tratamiento del cancer.
AU2004213752B2 (en) 2003-01-31 2008-10-23 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
US20040156846A1 (en) * 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
CA2519528C (en) 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
US7172751B2 (en) 2003-06-13 2007-02-06 Immunomedics, Inc. D-amino acid peptides
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
EP3037105B1 (de) 2003-06-27 2021-03-17 Amgen Fremont Inc. Auf die deletionsmutanten des epidermalen wachstumsfaktorrezeptors gerichtete antikörper und verwendungen davon
US8038983B2 (en) * 2003-07-29 2011-10-18 Immunomedics, Inc. Fluorinated carbohydrate conjugates
WO2005012493A2 (en) 2003-07-31 2005-02-10 Immunomedics, Inc. Anti-cd19 antibodies
EP1651663B1 (de) * 2003-08-08 2017-05-17 Immunomedics, Inc. Bispezifische antikörper zur induktion der apoptose in tumorzellen und erkrankten zellen
WO2005026325A2 (en) * 2003-09-10 2005-03-24 Surromed, Inc, Bivalent targeting of cell surfaces
US20050202020A1 (en) * 2004-01-09 2005-09-15 Jeffrey Ross Diagnosing and treating cancer
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
EP1610818A4 (de) * 2004-03-03 2007-09-19 Millennium Pharm Inc Modifizierte antikörper gegen ein prostataspezifisches membranantigen und verwendung dafür
KR20070036130A (ko) 2004-07-16 2007-04-02 화이자 프로덕츠 인코포레이티드 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
US20090214434A1 (en) * 2004-08-20 2009-08-27 O'dowd Dennis Hardy Method of detecting and treating allogenic cells responsible for endometriosis
DE602005022928D1 (de) 2004-11-30 2010-09-23 Abgenix Inc Antikörper gegen gpnmb und ihre verwendungen
EP1838737B1 (de) 2004-12-20 2011-04-06 Amgen Fremont Inc. Für humane matriptase spezifische bindungsproteine
CN101171034B (zh) 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20090226367A1 (en) * 2005-03-11 2009-09-10 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
WO2007059082A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
EP2551282A3 (de) 2005-03-23 2013-02-13 Genmab A/S Antikörper gegen CD38 zur Behandling von multiplem Myelom
WO2006104677A2 (en) 2005-03-24 2006-10-05 Millennium Pharmaceuticals, Inc. Antibodies that bind ov064 and methods of use therefor
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8642330B2 (en) * 2005-08-08 2014-02-04 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
EP1954311A4 (de) 2005-12-07 2009-12-23 Medarex Inc Ctla-4-antikörper-dosierungseskalationstherapien
RS52357B (en) 2005-12-13 2012-12-31 Medimmune Limited BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
CA2648846A1 (en) * 2006-04-07 2007-10-18 The Government Of The United States Of America As Represented By The Sec Retary, Department Of Health And Human Services Antibody compositions and methods for treatment of neoplastic disease
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
US9277295B2 (en) * 2006-06-16 2016-03-01 Cisco Technology, Inc. Securing media content using interchangeable encryption key
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
CN104043123B (zh) 2007-01-25 2019-08-13 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
AU2008227123B2 (en) 2007-03-15 2014-03-27 Ludwig Institute For Cancer Research Ltd. Treatment method using EGFR antibodies and src inhibitors and related formulations
MX2010001757A (es) * 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
WO2009039207A1 (en) * 2007-09-19 2009-03-26 Oncofluor, Inc. Method for imaging and treating organs and tissues
EP2090322A1 (de) * 2008-02-18 2009-08-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung von FSH-Rezeptorliganden zur Diagnose und Behandlung von Krebs
KR20110033233A (ko) * 2008-07-21 2011-03-30 이뮤노메딕스, 인코오포레이티드 개선된 치료 특성을 갖는 항체의 구조 변이체
WO2010032060A1 (en) 2008-09-19 2010-03-25 Medimmune Llc Antibodies directed to dll4 and uses thereof
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP2012513194A (ja) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ α５β１に向けられた標的結合剤およびその使用
US20120165340A1 (en) 2009-02-11 2012-06-28 Ludwing Institute For Cancer Research Ltd. Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
LT3912643T (lt) 2009-02-13 2023-02-10 Immunomedics Inc. Imunokonjugatai su ląstelės viduje skaldoma jungtimi
AU2010244142B2 (en) 2009-05-05 2016-07-21 Novimmune Sa Anti-IL-17F antibodies and methods of use thereof
EP3009455A1 (de) 2009-09-16 2016-04-20 Immunomedics Inc. Klasse-i-anti-cea-antikörper und verwendungen davon
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2011040973A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
JP2013506664A (ja) 2009-10-02 2013-02-28 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド 抗線維芽細胞活性化タンパク質抗体並びにその方法及び使用
US8785600B2 (en) 2009-10-23 2014-07-22 Millennium Pharmaceuticals, Inc. Anti-GCC antibody molecules and related compositions and methods
US8565892B2 (en) * 2009-10-31 2013-10-22 Qteris, Inc. Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
EP2523680A4 (de) * 2010-01-11 2013-06-19 Ct Molecular Med & Immunology Verstärkte zytotoxizität von antikörpern gegen cd74 und hla-dr mit interferon-gamma
EP2808344A1 (de) 2010-06-01 2014-12-03 Monash University Auf die Rezeptor-Tyrosinkinase C-MET gerichtete Antikörper
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
RS56599B1 (sr) 2010-06-15 2018-02-28 Genmab As Konjugati humanog antitela sa lekom protiv tkivnog faktora
DK3323830T3 (da) 2010-06-19 2023-09-25 Memorial Sloan Kettering Cancer Center Anti-gd2 antibodies
EP3345619A1 (de) 2010-10-19 2018-07-11 Mayo Foundation for Medical Education and Research Humane antikörper sowie diagnostische und therapeutische verwendungen davon zur behandlung neurologischer erkrankungen
EP3214442A1 (de) 2010-10-25 2017-09-06 F. Hoffmann-La Roche AG Behandlung von gastrointestinalen entzündungen und psoriasis und asthmaentzündung und psoriasis a
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US9211302B2 (en) 2011-01-17 2015-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulation of LRCH4 activity and therapeutic application thereof
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
CN103796678B (zh) 2011-04-20 2018-02-27 健玛保 针对her2的双特异性抗体
CN103501825B (zh) 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
PE20141937A1 (es) 2011-11-16 2014-12-18 Amgen Inc Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
EP2788020A4 (de) 2011-12-05 2015-04-29 Immunomedics Inc Therapeutische verwendung von anti-cd22-antikörpern zur induktion von trogozytose
CN111533804A (zh) 2012-02-06 2020-08-14 印希彼有限公司 Cd47抗体及其使用方法
MX356347B (es) 2012-04-17 2018-05-23 Mayo Found Medical Education & Res Anticuerpos humanos y secuencias de unión específicas de los mismos para su uso en apoplejía e isquemia o condiciones isquémicas.
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
KR20150023729A (ko) 2012-06-14 2015-03-05 암브룩스, 인코포레이티드 핵 수용체 리간드 폴리펩티드에 접합된 항-psma 항체
EP3632462A1 (de) 2012-07-06 2020-04-08 Genmab B.V. Dimerprotein mit dreifacher mutation
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
KR20220156667A (ko) 2013-01-10 2022-11-25 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
MX2015010115A (es) 2013-02-06 2016-05-31 Inhibrx Llc Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos.
CN105026423A (zh) 2013-03-14 2015-11-04 瑞泽恩制药公司 爱帕琳融合蛋白和其用途
CN105705165B (zh) 2013-03-15 2020-04-24 纪念斯隆-凯特琳癌症中心 高亲和力抗gd2抗体
BR122023002590B1 (pt) 2013-07-05 2023-12-05 Genmab A/S Anticorpo humanizado ou quimérico de ligação ao cd3 humano, anticorpo biespecífico, microrganismo, composição, composição farmacêutica, uso dos mesmos, método para produzir um anticorpo, composição de diagnóstico, método in vitro para detectar a presença de antígeno cd3, ou uma célula expressando cd3, em uma amostra, kit para detectar a presença de antígeno cd3, ou uma célula que expressa cd3, em uma amostra e anticorpo anti-idiotípico
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3033356B1 (de) 2013-08-14 2020-01-15 Sachdev Sidhu Antikörper gegen frizzled proteine und verwendung davon
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
EP3134439B1 (de) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk-antikörpermoleküle und verwendung davon für eine auf syk abzielende therapie
EP3160504B1 (de) 2014-06-24 2020-09-16 Immunomedics, Inc. Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
EP3166688A4 (de) 2014-07-08 2017-12-20 New York University Tau-bildgebungsliganden und deren verwendung in der diagnose und behandlung von tauopathie
UA127198C2 (uk) 2014-07-11 2023-06-07 Ґенмаб А/С Антитіло, яке зв'язує axl
CN117138060A (zh) 2014-10-07 2023-12-01 免疫医疗公司 抗体-药物缀合物的新辅助剂用途
CA2967026A1 (en) 2014-11-07 2016-05-12 Mayo Foundation For Medical Education And Research Treatment of neonatal hypoxia including impairments or effects thereof
EA034516B1 (ru) 2014-11-25 2020-02-14 Бристол-Маерс Сквибб Компани Способы и композиции для мечения радиоактивным изотопомf биологических препаратов
US10227408B2 (en) 2015-02-19 2019-03-12 Compugen Ltd. Anti-PVRIG antibodies and methods of use
IL296062A (en) 2015-03-17 2022-10-01 Memorial Sloan Kettering Cancer Center Antibodies against muc16 and their uses
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
WO2016201282A2 (en) 2015-06-12 2016-12-15 Ludwig Institute For Cancer Research Ltd TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
SI3313443T1 (sl) 2015-06-25 2023-11-30 Immunomedics, Inc. Kombiniranje protiteles proti HLA-DR ali proti TROP-2 z zaviralci mikrotubulov, zaviralci PARP, zaviralci brutonove kinaze ali zaviralci fosfoinozitid 3-kinaze pomembno izboljša izid zdravljenja pri raku
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
SI3316885T1 (sl) 2015-07-01 2021-09-30 Immunomedics, Inc. Imunokonjugati protitelo-SN-38 z linkerjem CL2A
CN108368171A (zh) 2015-07-10 2018-08-03 根马布股份公司 用于癌症治疗的axl特异性抗体-药物缀合物
WO2017009712A1 (en) 2015-07-13 2017-01-19 Compugen Ltd. Hide1 compositions and methods
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
EP3334453A4 (de) 2015-08-13 2019-02-06 New York University Antikörperbasierte, für das verkürzte asp421-epitop von tau spezifische moleküle und deren verwendungen in der diagnose und behandlung von tauopathie
EP3334761B1 (de) 2015-08-13 2023-07-19 New York University Antikörperbasierte, für das {p}ser404-epitop von tau selektive moleküle und deren verwendungen in der diagnose und behandlung von tauopathie
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
US10335608B2 (en) 2016-04-20 2019-07-02 Theralase Technologies, Inc. Photodynamic compounds and methods for activating them using ionizing radiation and/or other electromagnetic radiation for therapy and/or diagnostics
WO2017189279A1 (en) 2016-04-27 2017-11-02 Immunomedics, Inc. Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
EP3827849A1 (de) 2016-05-19 2021-06-02 Bristol-Myers Squibb Company Immunmodulatoren für pet-bildgebung
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
SI3484916T1 (sl) 2016-07-12 2021-08-31 H. Lundbeck A/S Protitelesa, specifična za hiperfosforiliran Tau, in postopki za uporabo le-teh
CN117330747A (zh) 2016-07-15 2024-01-02 武田药品工业株式会社 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
US20190276549A1 (en) 2016-11-01 2019-09-12 Genmab B.V. Polypeptide variants and uses thereof
WO2018109058A1 (en) 2016-12-16 2018-06-21 H. Lundbeck A/S Agents, uses and methods
CN110267985B (zh) 2017-01-04 2023-05-23 H.隆德贝克有限公司 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
CA3051484A1 (en) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
CN110392570A (zh) 2017-03-27 2019-10-29 免疫医疗公司 用沙妥珠单抗格维替康和rad51抑制剂治疗表达trop-2的三阴性乳腺癌
EP3606964A4 (de) 2017-04-03 2020-12-09 Immunomedics, Inc. Subkutane verabreichung von antikörper-arzneimittelkonjugaten zur krebstherapie
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
US20210107988A1 (en) 2018-01-24 2021-04-15 Genmab B.V. Polypeptide variants and uses thereof
TW202019518A (zh) 2018-07-13 2020-06-01 丹麥商珍美寶股份有限公司 Ｃｄ３８抗體之變體及其用途
CA3118186A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd Humanized and variant tgf-.beta.1 specific antibodies and methods and uses thereof
US20210388074A1 (en) 2018-11-05 2021-12-16 Ludwig Institute For Cancer Research Ltd. Humanized and variant tgf-beta3 specific antibodies and methods and uses thereof
MX2021005751A (es) 2018-11-16 2021-10-01 Memorial Sloan Kettering Cancer Center Anticuerpos contra mucina 16 y métodos de uso de los mismos.
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
WO2020237491A1 (en) 2019-05-28 2020-12-03 Shanghaitech University Composition and methods to treat ectodermal dysplasia 2, clouston type
WO2021141492A1 (en) 2020-01-10 2021-07-15 Kling Biotherapeutics B.V. Epithelial cadherin-specific antibodies
EP3909601A1 (de) 2020-05-11 2021-11-17 LeukoCom GmbH Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
EP4169949A1 (de) 2020-06-23 2023-04-26 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-cd38-antikörper und verwendung davon
CN116964085A (zh) 2021-03-12 2023-10-27 根马布股份公司 非激活抗体变体
EP4342497A1 (de) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antikörper mit reduzierter bindungsaffinität für antigen

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683066A (en) 1969-01-14 1972-08-08 Ivan Ascanio Technetium 99m colloidal composition
US3683006A (en) * 1970-09-09 1972-08-08 Syntex Corp Cyclodecapentaene compounds
US3927193A (en) * 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US4087156A (en) * 1975-11-07 1978-05-02 International Telephone & Telegraph Corporation Optical fiber transmission mixer and method of making same
GB1535847A (en) 1976-03-19 1978-12-13 Radiochemical Centre Ltd Technetium-99m labelled tin colloid for body scanning
US4036945A (en) * 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4234561A (en) * 1978-02-06 1980-11-18 Research Corporation Antigen for early pregnancy test and contraceptive vaccine
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
US4311688A (en) * 1979-10-29 1982-01-19 Serono Laboratories Inc. Composition and method for cancer detection in humans
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
WO1981002522A1 (en) 1980-03-03 1981-09-17 M Goldenberg Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4440747A (en) * 1980-09-30 1984-04-03 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibody-ricin hybrids as a treatment of murine graft-versus-host disease
US4468457A (en) * 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
DE3129906C3 (de) 1981-07-24 1996-12-19 Schering Ag Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4434156A (en) * 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
JPS58201994A (ja) * 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US5286647A (en) * 1982-05-21 1994-02-15 University Of California Human-human hybridomas for neoplasms
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
DE3237573A1 (de) 1982-10-09 1984-04-12 Hoechst Ag, 6230 Frankfurt Technetium-99m-tri- und tetraphosphonate zur szintigraphischen dastellung res-haltiger organe und der lymphgefaesse und verfahren zu deren herstellung
US4460459A (en) * 1983-02-16 1984-07-17 Anschutz Mining Corporation Sequential flotation of sulfide ores
US4500508A (en) 1983-05-03 1985-02-19 The United States Of America As Represented By The United States Department Of Energy Radionuclide labeled lymphocytes for therapeutic use
EP0149709B2 (de) 1983-07-29 1995-11-29 Milton David Goldenberg Verfahren zur Erhöhung der Zielspezifizität in Antikörperbestimmungen und zur Räumung von nichtzielspezifischen diagnostischen und therapeutischen Faktoren
CA1242643A (en) 1983-08-12 1988-10-04 Eric T. Fossel Nmr imaging utilizing chemical shift reagents
US4732864A (en) * 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4620971A (en) 1983-12-22 1986-11-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Indium-bleomycin complex
US4578335A (en) * 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
US5144010A (en) * 1984-08-27 1992-09-01 The Trustees Of Columbia University In The City Of New York Method of producing monoclonal auto-anti-idiotypic antibodies
NZ212437A (en) * 1985-06-17 1992-06-25 Mark Philip Best Site-directed antibody conjugates, and their preparation
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) * 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5011684A (en) * 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5053491A (en) * 1985-12-13 1991-10-01 Washington University School Of Medicine Monoclonal antibodies and cell lines for parathyroid tissue-specific antigen
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5670151A (en) * 1986-04-28 1997-09-23 Chiron Corporation Method for controlling hyperproliferative diseases
US4742000A (en) * 1986-05-02 1988-05-03 University Of Chicago Antibody to human progesterone receptor and diagnostic materials and methods
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US5478576A (en) * 1986-07-03 1995-12-26 Advanced Magnetics, Inc. Arabinogalactan derivatives and uses thereof
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4946675A (en) 1987-05-27 1990-08-07 Xoma Corporation Hepatic blocking agents
ATE137119T1 (de) * 1987-08-17 1996-05-15 Us Commerce Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen
EP0377657A1 (de) * 1987-08-19 1990-07-18 Centocor, Inc. Menschliches ovarialtumor assoziertes antigen, das spezifisch ist für den antikörper ov-tl3
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US5208021A (en) * 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5091313A (en) * 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
DE68926294T2 (de) * 1988-02-18 1996-09-19 Ks Biomedix Ltd Antigen gegen diabetes
US5112954A (en) * 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents
US5011689A (en) * 1988-03-17 1991-04-30 T. Paul Misenko Composition of matter and method for treating poison ivy
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
JPH03504438A (ja) * 1988-03-30 1991-10-03 アーチ　デベロプメント　コーポレイション アンドロジェンレセプターを含むｄｎａ結合蛋白質
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
US5152980A (en) * 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
US5006652A (en) 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
US5420105A (en) * 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
US5144007A (en) * 1988-11-03 1992-09-01 La Jolla Cancer Research Foundation Thyroid hormone receptor
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
GB2228262B (en) * 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
AU6164290A (en) 1989-07-31 1991-03-11 Vasocor Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
EP0493446B1 (de) * 1989-09-15 1997-01-29 Tanox Biosystems, Inc. Behandlung von einer autoimmun-krankheit
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2152216T3 (es) 1989-12-14 2001-02-01 Sloan Kettering Inst Cancer Usos terapeuticos de la region hipervariable del anticuerpo monoclonal m195 y constructos de la misma.
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
WO1991013974A1 (en) * 1990-03-14 1991-09-19 The Biomembrane Institute Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
WO1991016069A1 (en) * 1990-04-17 1991-10-31 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Selective cytotoxic reagents comprising toxic moieties derived from mammalian proteins
US5223241A (en) * 1990-10-01 1993-06-29 The General Hospital Corporation Method for early detection of allograft rejection
US5322699A (en) * 1991-02-04 1994-06-21 The Rockefeller University Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
WO1992014493A1 (en) * 1991-02-20 1992-09-03 Christopher Capelli Non-protein intracellular receptor binding conjugates and a method of use thereof
US5326559A (en) * 1991-05-16 1994-07-05 Miller D Douglas Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
US5298499A (en) * 1991-07-05 1994-03-29 Research Triangle Institute S-2-(substituted ethylamino)ethyl phosphorothioates
US5225182A (en) * 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
BR9207175A (pt) * 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US5411985A (en) * 1993-05-17 1995-05-02 Merck & Co., Inc. Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US6653104B2 (en) * 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US7074403B1 (en) * 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
AU2003208415B2 (en) * 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use

Also Published As

Publication number Publication date
AU3937093A (en) 1993-11-08
HK1062647A1 (en) 2004-11-19
US7811570B2 (en) 2010-10-12
ATE441667T1 (de) 2009-09-15
WO1993019668A1 (en) 1993-10-14
EP1393750B1 (de) 2009-09-02
EP1393750A3 (de) 2004-03-31
JP2010184948A (ja) 2010-08-26
EP1384488A2 (de) 2004-01-28
EP1375519A2 (de) 2004-01-02
US20110117105A1 (en) 2011-05-19
JP2006083183A (ja) 2006-03-30
DE69334293D1 (de) 2009-10-15
EP1393750A2 (de) 2004-03-03
AU5946096A (en) 1996-09-12
EP0637933A4 (de) 1996-06-26
JP2000226338A (ja) 2000-08-15
US5776094A (en) 1998-07-07
EP1384488A3 (de) 2004-06-23
IL127509A0 (en) 1999-10-28
ATE279215T1 (de) 2004-10-15
EP1375519A3 (de) 2004-06-30
US20060067885A1 (en) 2006-03-30
DK0637933T3 (da) 2005-02-28
ATE441438T1 (de) 2009-09-15
EP1384488B1 (de) 2009-09-02
DE69333658T2 (de) 2006-03-02
IL105302A (en) 1999-04-11
PT637933E (pt) 2004-12-31
AU5945896A (en) 1996-09-12
AU1131899A (en) 1999-03-04
IL127509A (en) 2001-03-19
DK1393750T3 (da) 2009-12-14
US5776093A (en) 1998-07-07
CA2133833A1 (en) 1993-10-14
IL127510A0 (en) 1999-10-28
AU674846B2 (en) 1997-01-16
ES2229207T3 (es) 2005-04-16
IL105302A0 (en) 1993-08-18
US6331175B1 (en) 2001-12-18
EP0637933B1 (de) 2004-10-13
AU702089B2 (en) 1999-02-11
US5776095A (en) 1998-07-07
CA2133833C (en) 2009-12-22
EP0637933A1 (de) 1995-02-15
US20020052594A1 (en) 2002-05-02
IL127510A (en) 2001-01-11
US5697902A (en) 1997-12-16
JPH07508974A (ja) 1995-10-05
DE69333658D1 (de) 2004-11-18

Similar Documents

Publication Publication Date Title
ATE441667T1 (de) Antikírper für die behandlung von einer immunerkrankung
ATE264099T1 (de) Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
CA2194369A1 (en) Methods and compositions for the specific coagulation of vasculature
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
DE69815122D1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
CY1112845T1 (el) Παραγωγα της 1-δεοξυ-γαλακτονογιριμυκινης και η χρηση τους στη θεραπεια αθροιστικων λυσοσωμικων ασθενειων μεσω ενισχυσης της λυσοσωμικης α-γαλακτοσιδασης α
CA2131168A1 (en) Decontaminating blood components
NZ237165A (en) Ophthalmological medicaments consisting of a complex of a glucan sulphate and an ophthalmological agent
ATE249819T1 (de) Präparate zur äusserlichen anwendung zur behandlung von dermatosen
ATE492304T1 (de) Verwendung von dreidimensionalen prothesen, die hyaluronsäurederivate enthalten
AU3401093A (en) Therapeutic agent for threatened abortion
DE59304087D1 (de) Placentaextrakt und Verfahren zu seiner Herstellung
Waite An Assessment of the Postsurgical Results Following the Combined Laterally Positioned Flap and Gingival Graft Procedure.
EP0539516A4 (de)
CA2170289A1 (en) A method of treating liver disease and like indications with vasodilating agents
UA10259A (uk) Протинабряковий лікарський препарат "нейрополіосм"
Klitsch Hysterectomy and managed care
UA7163A (uk) Спосіб відновлення ушкоджених тканин людини чи тварини
UA21935C2 (uk) Спосіб hормалізації фуhкцій оргаhів і систем біооб'єкту
GEP20002177B (en) Ointment “Levaskani” for Treatment of Wounds and Burns

Legal Events

Date Code Title Description
8364 No opposition during term of opposition